Recent Innovations in Oral Contraception
Recent Innovations in Oral Contraception
复制标题
DOI：
10.1055/s-0030-1248139
复制
发表时间：
2010-03-01
影响因子：
2.7
通讯作者：
Jacobs, Adam
中科院分区：
文献类型：
--
作者：
Cremer, Miriam;Phan-Weston, Scarlett;Jacobs, Adam
传统形式的口服避孕药在无避孕间隔期（HFI）内包含21天含避孕药的药丸和7天安慰剂。自2003年以来，食品和药物管理局已经批准了24/4，84/7和365天的方案。这些方案HFI都试图减少出血和尿道相关的副作用。这些方案的安全性和有效性与传统的21/7关闭相当。延长的治疗方案与高患者满意度相关。使用延长方案的女性出血模式相似或更短，沿着月经症状的改善。其中一种新配方含有新的曲螺酮，它具有抗盐皮质激素和抗雄激素的特性。本综述总结了美国口服避孕药新剂型的数据，并对屈螺酮的现有文献进行了总结。
Traditional forms of oral contraception contain 21 days of hormone-containing pills and 7 days of placebo during the hormone-free Interval (HFI). Since 2003, the Food and Drug Administration has approved 24/4, 84/7,and 365-day regimens. These regimens the HFI in all attempt to decrease bleeding and menstrual-associated side effects. Safety and efficacy of these regimens is comparable with traditional 21/7 closing. Extended regimens are associated with high patient satisfaction. Bleeding patterns are similar or shorter in women using extended regimens, along with improvement in menstrual symptoms. One of the new formulations contains the new progestin drospirenone, which has antimineralocorticoid and antiandrogenic properties. This review summarizes the data about new formulations of oral contraception available in the United Sates and also provides a summary of the current literature on drospirenone.